Prolonging the lives of African-Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study.

African American metastatic breast cancer palbociclib real-world study

Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
22 Mar 2024
Historique:
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 22 3 2024
Statut: aheadofprint

Résumé

This study used These results support the use of palbociclib with an AI as a first treatment for African-Americans with HR+/HER2- MBC.

Identifiants

pubmed: 38517416
doi: 10.2217/fon-2023-1079
doi:

Banques de données

ClinicalTrials.gov
['NCT05361655']

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Hope S Rugo (HS)

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

Xianchen Liu (X)

Pfizer Inc, New York, NY, USA.

Benjamin Li (B)

Pfizer Inc, New York, NY, USA.

Lynn McRoy (L)

Pfizer Inc, New York, NY, USA.

Connie Chen (C)

Pfizer Inc, New York, NY, USA.

Rachel M Layman (RM)

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Tiah Tomlin-Harris (T)

My Style Matters, Inc, Atlanta, GA, USA.

Adam Brufsky (A)

UPMC Hillman Cancer Center, Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

Classifications MeSH